Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DPYD | Q12882 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 5/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482574 | 1.00 | CYP3A4 (0.75) | CYP3A4CRBNALDH1A1LMNADPYD | |
| SCHEMBL1764958 | 0.94 | CYP3A4 (0.66) | CYP3A4CRBNALDH1A1LMNADPYD | |
| SCHEMBL483525 | 0.92 | CYP3A4 (0.63) | CYP3A4CRBNALDH1A1LMNADPYD | |
| SCHEMBL483527 | 0.92 | CYP3A4 (0.63) | CYP3A4CRBNALDH1A1LMNADPYD | |
| SCHEMBL2490522 | 0.89 | CYP3A4 (0.59) | CYP3A4CRBNALDH1A1LMNATYMS | |
| SCHEMBL2490521 | 0.89 | CYP3A4 (0.59) | CYP3A4CRBNALDH1A1LMNATYMS | |
| SCHEMBL2127562 | 0.88 | CYP3A4 (0.76) | CYP3A4CRBNTRPV1PADI4TNFRSF1A | |
| SCHEMBL1542924 | 0.88 | CYP3A4 (0.76) | CYP3A4CRBNTRPV1PADI4TNFRSF1A | |
| SCHEMBL2745165 | 0.88 | CYP3A4 (0.58) | CYP3A4CRBNALDH1A1LMNATYMS | |
| SCHEMBL2745167 | 0.88 | CYP3A4 (0.58) | CYP3A4CRBNALDH1A1LMNATYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | claimed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2411352-A2 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111436-A2 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | CYP3A4 1569/4885CRBN 2389/4885ALDH1A1 2957/4885 |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885CRBN 1341/4885ALDH1A1 938/4885 |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | CYP3A4 1569/4885CRBN 2389/4885ALDH1A1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.